fbpx

Day

October 8, 2020
Aarhus, Denmark, 6 October 2020 – NMD Pharma A/S, a biotech company leading in the development of novel therapeutics for neuromuscular disorders, today announces that the first subject has been dosed in a Phase I/IIa clinical trial of NMD670, NMD Pharma’s lead program in development to treat the symptoms of myasthenia gravis (MG). The trial...

News

90 million to 18 Talented Researchers
19. October 2020
Søren Dinesen Lumdbeckfonden
Psychiatry research leads to prestigious science prize
13. October 2020
Christian Sandøe Musaeus Lundbeckfonden
Concentrating on Dementia
13. October 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge